Brachytherapy and bivalirudin evaluation study

American Heart Journal

Volumn 150, Issue 4, 2005, Pages 832-837

  Kuchulakanti, Pramod ^a   Wolfram, Roswitha ^a   Torguson, Rebecca ^a   Rha, Seung Woon ^a   Cheneau, Edouard ^a   Pinnow, Ellen E ^a   Canos, Daniel ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Kent, Kenneth M ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; HIRULOG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BETA RADIATION; BLEEDING; BOLUS INJECTION; BRACHYTHERAPY; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; GAMMA RADIATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RADIATION EXPOSURE; REOPERATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BRACHYTHERAPY; CORONARY STENOSIS; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 25844511771     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.11.013     Document Type: Article

References (22)

1. J.A. Bittl Bivalirudin for percutaneous coronary interventions: development perspective J Invasive Cardiol 12 Suppl F 2000 2F 6F
2. A.M. Lincoff, N.S. Kleiman, and K. Kottke-Marchant Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) Am Heart J 143 2002 847 853
3. A.M. Lincoff, J.A. Bittl, and R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
4. A.M. Lincoff, J.A. Bittl, and N.S. Kleiman Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 Trial) Am J Cardiol 93 2004 1092 1096
5. J.M. Maraganore, P. Bourdon, and J. Jablonski Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin Biochemistry 29 1990 7095 7101
6. S.M. Bates, and J.I. Weitz The mechanism of action of thrombin inhibitors J Invasive Cardiol 12 Suppl F 2000 27F 32F
7. P.J. Hogg, and P.E. Bock Modulation of thrombin and heparin activities by fibrin Thromb Haemost 77 1997 424 433
8. D.L. Becker, J.C. Fredenburgh, and A. Stafford Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II J Biol Chem 274 1999 6226 6233
9. P.J. Hogg, C.M. Jackson, and J.K. Labanowski Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen J Biol Chem 271 1996 26088 26095
10. E.W. Davie Biochemical and molecular aspects of the coagulation cascade Thromb Haemost 74 1995 1 6
11. R. Waksman, B. Bhargava, and R.L. White Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis Circulation 101 2000 1895 1898
12. R. Waksman, R.L. White, and R.C. Chan Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis Circulation 101 2000 2165 2171
13. J.A. Bittl, J. Strony, and J.A. Brinker Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators N Engl J Med 333 1995 764 769
14. A.E. Ajani, and R. Waksman The WRIST series-what have we learnt? Herz 27 2002 23 29
15. P. Kuchulakanti, L. Satler, and S.W. Rha Case report bivalirudin associated intracoronary thrombosis during gamma brachytherapy and its experimental validation in acute swine model Catheter Cardiovasc Interv 62 2004 209 213
16. J.I. Witting, P. Bourdon, and D.V. Brezniak Thrombin-specific inhibition by and slow cleavage of hirulog-1 Biochem J 283 1992 737 743
17. M.A. Parry, J.M. Maraganore, and S.R. Stone Kinetic mechanism for the interaction of Hirulog with thrombin Biochemistry 33 1994 14807 14814
18. S. Sharma, B. Bhambi, and W. Nyitray Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure J Cardiovasc Pharmacol Ther 8 2003 9 15
19. J.A. Bittl, and F. Feit A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators Am J Cardiol 82 1998 43P 49P
20. J.A. Bittl, B.R. Chaitman, and F. Feit Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study Am Heart J 142 2001 952 959
21. R. Waksman, A.E. Ajani, and L. Gruberg Use of IIb/IIIa inhibitors in patients with in-stent restenosis treated with intracoronary gamma-radiation: Integrilin WRIST Catheter Cardiovasc Interv 62 2004 162 166
22. R. Waksman, B. Bhargava, and L. White Intracoronary β-radiation therapy inhibits recurrence of in-stent restenosis Circulation 101 2000 1895 1898